Iclusig News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Iclusig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Iclusig Today - Breaking & Trending Today
Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia. ....
Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC ( Optimizing In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ponatinib (Iclusig ) over a range of three starting doses (45mg, 30mg, 15mg) followed by dose reduction to 15mg with the aim of optimizing efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant to prior tyrosine kinase inhibitor (TKI) therapy met its primary endpoint. ....